Smith & Nephew faces long and painful activist fix
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Aimee Donnellan
LONDON, July 4 (Reuters Breakingviews) -Smith & Nephew SN.L should prepare for a long and painful activist treatment. On Thursday, Swedish investor Cevian Capital announced it had taken a 5% stake in the $11 billion UK-listed maker of hip joints and wound care kit. Its medicine is likely to involve stripping out costs. If that fails, more radical remedies like a breakup may be necessary.
Smith & Nephew has many ingredients activists look for in a target. Its share price has fallen 42% over the past five years, whereas the FTSE 100 Index .FTSE is up by 10%. Endless management churn can’t have helped: during that same period the group has had three CEOs and three chief financial officers. Its boss, Deepak Nath, has introduced a 12-point plan to increase the company’s performance.
Investors, however, are not convinced. Including debt, Smith & Nephew is valued at $14 billion, just 13 times its expected operating profit in 2025, according to LSEG data, a steep discount to its five-year average of 18 times. Cevian has not yet disclosed its demands, but the activist could push Nath to take a bigger axe to Smith & Nephew’s bloated cost base, which resulted in an operating margin of just 17% last year. U.S.-listed rival Stryker SYK.N generated a 24% margin.
Assume Smith & Nephew can close half the profitability gap with Stryker, and its EBIT margin would reach 21%. Apply that to the $6.7 billion of revenue the London-listed firm is expected to deliver in 2027, and operating profit could total $1.4 billion that year. Next, assume a leaner, more profitable Smith & Nephew is valued at 17 times forward EBIT, again closing half the gap with Stryker’s multiple, and its enterprise value could exceed $24 billion in two years. That’s nearly 70% higher than its current worth.
If Nath fails, deeper surgery may be necessary. Last year the orthopaedic division that makes artificial hip and knee joints was the slowest growing of Smith & Nephew’s business units. Selling that to a rival, like Stryker, could free up cash to invest in the other two units, wound care and sports injuries. Alternatively, switching its primary listing to the United States may attract more investors, and a higher valuation. But a recovery is likely to take time. As activist campaigns go, Smith & Nephew will be more than a quick fix.
Follow @aimeedonnellan on X
CONTEXT NEWS
Activist investor Cevian said on July 4 it has taken a 5% stake in Smith & Nephew, the London-listed manufacturer of medical devices.
Shares in Smith & Nephew were up 6.3% at 1,047 pence by 0734 GMT.
Graphic: Smith & Nephew’s valuation is lagging rivals https://reut.rs/3VOCqIp
Editing by Neil Unmack and Oliver Taslic
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
